What are the effects of drug treatments for panic disorder?

This article is part of a new initiative in Evidence-based Mental Health, namely the serialisation of chapters of Clinical Evidence (a summary of the best available evidence on common clinical interventions updated regularly by the BMJ Publishing Group). This article is based on material presented in: Kumar S, Oakley-Browne M. Panic disorder. Clinical Evidence 2002; 8: 1003–9. For this review, Clinical Evidence searched and appraised material published until May 2002. Studies with follow up periods of less than 6 months were excluded.

A panic attack is a period in which there is sudden onset of intense apprehension, fearfulness or terror, often associated with feelings of impending doom. Panic disorder occurs when there are recurrent, unpredictable attacks followed by at least 1 month of persistent concern about having another panic attack; worry about the possible implications or consequences of the panic attacks, or a significant behavioural change related to the attacks. The term “panic disorder” excludes panic attacks attributable to the direct physiological effects of a general medical condition, substance or another mental disorder. Panic disorder is sometimes categorised as “with” or “without agoraphobia.” Alternative categorisations focus on phobic anxiety disorders and specify agoraphobia with or without panic disorder.

Prevalence
Panic disorder often starts around 20 years of age (between late adolescence and the mid-30s). Lifetime prevalence is 1–3%, and panic disorder is more common in women than in men. An Australian community study found 1 month prevalence rates for panic disorder (with or without agoraphobia) of 0.4% using International Classification of Diseases (ICD)-10 diagnostic criteria and of 0.5% using Diagnostic and Statistical Manual (DSM)-IV diagnostic criteria.

Risk factors
Stressful life events tend to precede the onset of panic disorder, although a negative interpretation of these events in addition to their occurrence has been suggested as an important causal factor. Panic disorder is associated with major depression, social phobia, generalised anxiety disorder, obsessive compulsive disorder, and a substantial risk of drug and alcohol abuse. It is also associated with avoidant, histrionic and dependent personality disorders.

Prognosis
The severity of symptoms in people with panic disorder fluctuates considerably, with periods of no attacks, or only mild attacks with few symptoms, being common. There is often a long delay between the initial onset of symptoms and presentation for treatment. Recurrent attacks may continue for several years, especially if associated with agoraphobia. Reduced social or occupational functioning varies among people with panic disorder and is worse in people with associated agoraphobia. Panic disorder is also associated with an increased rate of attempted, but unsuccessful, suicide.

Key messages

<table>
<thead>
<tr>
<th>Evidence that treatment is beneficial</th>
<th>Trade off between benefits and harms</th>
</tr>
</thead>
<tbody>
<tr>
<td>tricyclic antidepressants (imipramine)</td>
<td>benzodiazepines</td>
</tr>
<tr>
<td>selective serotonin reuptake inhibitors</td>
<td>Unknown effectiveness</td>
</tr>
<tr>
<td>monoamine oxidase inhibitors</td>
<td>buspirone</td>
</tr>
</tbody>
</table>

Benzodiazepines
One systematic review and one additional randomised trial have found that alprazolam versus placebo significantly reduces the number of panic attacks and improves symptoms. However, benzodiazepines are associated with a wide range of adverse effects, both during their use and after treatment has been withdrawn.

Buspirone
Randomised controlled trials found insufficient evidence on the effects of buspirone versus placebo.

Monoamine oxidase inhibitors
We found no randomised controlled trials on the effects of monoamine oxidase inhibitors.

Selective serotonin reuptake inhibitors
Two systematic reviews and one additional randomised controlled trial have found that selective serotonin reuptake inhibitors versus placebo improve symptoms in panic disorder. One randomised controlled trial found that discontinuation of sertraline in people with a good response significantly increased exacerbation of symptoms.

Tricyclic antidepressants (imipramine)
One systematic review and subsequent randomised controlled trials have found that imipramine versus placebo significantly improves symptoms. One randomised controlled trial found that imipramine significantly reduced relapse rates over 12 months.

Treatment aims
To reduce the severity and frequency of panic attacks, phobic avoidance, and anticipatory anxiety; to improve social and occupational functioning, with minimal adverse effects of treatment.
Outcomes

Measures of panic attacks, agoraphobia, and associated disability (self reported and clinician rated, before and after treatment and longer term) using general scales or specific scales for panic disorder (eg the panic and agoraphobia scale, the mobility inventory for agoraphobia).

What are the effects of tricyclic antidepressants for panic disorder?

One systematic review and subsequent randomised controlled trials have found that imipramine versus placebo improves symptoms in people with panic disorder. One randomised controlled trial found that imipramine reduced relapse rates in people with panic disorder.

BENEFITS

We found one systematic review,11 one additional randomised controlled trial,14 and two subsequent randomised controlled trials.13 18 The systematic review (search date not stated, 27 randomised controlled trials, 2348 people) compared imipramine, selective serotonin reuptake inhibitors (paroxetine, fluvoxamine, zimelidine and clomipramine), and alprazolam versus placebo and versus each other.13 It found that imipramine versus placebo significantly increased the number of people judged to have improved (p<0.0001).

The additional randomised controlled trial (181 people with panic disorder with or without agoraphobia) compared 3 treatments: oral imipramine (maximum dose 225 mg); oral alprazolam (maximum dose 10 mg); and placebo.14 It found that imipramine versus placebo reduced the number of panic attacks after 8 months (results presented graphically, significance not calculated).

The first subsequent randomised controlled trial (56 adults with panic disorder and agoraphobia in stable remission after 24 weeks treatment with oral imipramine) comparing oral imipramine (2.25 mg/kg daily) versus placebo found that significantly fewer people taking imipramine relapsed after 12 months (1/29 [3%] with imipramine v 10/27 [37%] with placebo; RR 0.09, 95% CI 0.01 to 0.68; NNT 5, 95% CI 3 to 14).15

The second subsequent randomised controlled trial (312 people) compared five groups: oral imipramine (maximum dose 300 mg daily); cognitive behavioural therapy; placebo; cognitive behavioural therapy plus oral imipramine (maximum dose 300 mg daily); and cognitive behavioural therapy plus placebo.16 It found that imipramine versus placebo significantly increased the number of people judged to have responded using the panic disorder severity scale after 6 months (38% response rate with imipramine v 13% response rate with placebo; absolute numbers not provided; p=0.02).

HARMS

Adverse effects associated with imipramine treatment included blurred vision, tachycardia, palpitations, blood pressure changes, insomnia, nervousness, malaise, dizziness, headache, nausea, vomiting, and reduced appetite.14 17

COMMENT

The review included clomipramine as a selective serotonin reuptake inhibitor. This drug is also often described as a tricyclic antidepressant.13 The review used improvement as an outcome measure without a clear definition of this term. In the additional randomised controlled trial and the second subsequent randomised controlled trial, flexible dosing was used according to tolerance and therapeutic need.14 15 In the subsequent randomised controlled trial comparing imipramine versus placebo, relapse rate was not clearly defined.16

What are the effects of selective serotonin reuptake inhibitors (SSRI) for panic disorder?

Two systematic reviews and one additional randomised controlled trial have found that selective serotonin reuptake inhibitors versus placebo improve symptoms in panic disorder. One randomised controlled trial found that discontinuation of sertraline in people with a good response significantly increased exacerbation of symptoms.

BENEFITS

We found two systematic reviews,13 19 one additional randomised controlled trial,19 and one subsequent randomised controlled trial.19 The first systematic review (search date not stated, 27 randomised controlled trials, 2348 people) found that selective serotonin reuptake inhibitors (paroxetine, fluvoxamine, zimelidine and clomipramine) versus placebo significantly increased the number of people who improved (p<0.0001).

The second systematic review (search date not stated, 12 randomised controlled trials, 1741 people) only reported combined results as an effect size against placebo (effect size 0.55), and did not report statistical significance.11

The additional randomised controlled trial (279 people) compared five groups: oral citalopram (10 or 15 mg daily); oral citalopram (20 or 30 mg daily); oral citalopram (40 or 60 mg daily); oral clomipramine (60 or 90 mg daily); and placebo.20 It found that citalopram (at all doses) versus placebo significantly increased the number of people who responded (defined as no panic attacks and either no episodic increases in anxiety or only slight increases in anxiety precipitated by definite events or activities) after 12 months (citalopram 10 or 15 mg daily v placebo p=0.05; citalopram 20 or 30 mg daily v placebo p=0.001; citalopram 40 or 60 mg daily v placebo p=0.003; results presented graphically).

The subsequent randomised controlled trial (182 people who had responded to open label sertraline for 52 wks) compared double blind placebo (discontinuation of sertraline) versus sertraline for 28 weeks.21 It found significantly more people on placebo had exacerbation of symptoms (33% with placebo v 13% with sertraline, p=0.005; CI not available).

HARMS

The additional randomised controlled trial reported that harms associated with citalopram included headache, tremor, dry mouth, and somnolence.19

COMMENT

The first review included clomipramine as a selective serotonin reuptake inhibitor, although this drug is often described as a tricyclic antidepressant.13 In addition, the review used improvement as an outcome measure without clearly defining this term. In the additional randomised controlled trial, only just over half of people (28/54 [52%]) completed the trial; analysis was by intention to treat and people who withdrew from the trial were counted as treatment failures.31 The randomised controlled trial used flexible dosing according to tolerance and therapeutic need. Selective serotonin reuptake inhibitors can cause initial increased anxiety, which can exacerbate a tendency to focus on internal sensations and to avoid situations that trigger these sensations (catastrophise somatic sensations). Education about this event is likely to improve adherence with medication. The second systematic review found smaller randomised controlled trials were associated with larger effect sizes suggesting the possibility of publication bias.19
What are the effects of monoamine oxidase inhibitors for panic disorder?

We found no evidence on the effects of monoamine oxidase inhibitors in panic disorder.

We found no systematic review and no randomised controlled trials. We found no evidence of harms associated specifically with the use of monoamine oxidase inhibitors in the long term treatment of panic disorder. Our search strategy excluded studies with follow up of less than 6 months.

The review used improvement as an outcome measure without clearly defining this term. The individual randomised controlled trial used flexible dosing according to tolerance and therapeutic need. Many randomised controlled trials of psychological and pharmacological treatments (even those not involving benzodiazepines) allowed people to receive small amounts of anxiolytic drugs during the study because benzodiazepine abuse is quite prevalent in people who suffer from panic disorder.

What are the effects of buspirone for panic disorder?

Two randomised controlled trials found insufficient evidence on the effects of buspirone in people with panic disorder.

What are the effects of benzodiazepines for panic disorder?

One systematic review and one additional randomised controlled trial have found that alprazolam reduces the numbers of panic attacks and improves symptoms in people with panic disorder. Benzodiazepines are associated with a wide range of adverse effects, both during their use and after treatment has been withdrawn.

Harms

The randomised controlled trials did not report harms.

Benefits

We found one systematic review (search date not stated, 27 randomised controlled trials, 2348 people), and one additional randomised controlled trial. The review found that alprazolam versus placebo significantly increased the number of people judged to have improved (p < 0.0001). The additional randomised controlled trial (181 people with panic disorder with or without agoraphobia) compared three treatments: oral alprazolam (maximum 10 mg daily), oral imipramine (maximum 225 mg daily), and placebo. It found that alprazolam versus placebo was associated with fewer panic attacks after 8 months (results presented graphically; significance not calculated).

Harms

The systematic review did not report harms. Adverse effects associated with alprazolam include sedation, insomnia, memory lapses, nervousness, irritability, dry mouth, tremor, impaired coordination, constipation, urinary retention, altered libido, and altered appetite. We found one non-systematic review of the effects of benzodiazepines in anxiety disorder in people with a history of substance abuse or dependence. The review reported that the mortality of long term benzodiazepine users was no higher than matched controls. It reported that the most pronounced adverse effects followed sudden withdrawal and included tinnitus, paraesthesia, vision disturbance, depersonalisation, seizures, withdrawal psychosis, and persistent discontinuation syndrome.
Difficulties developing evidence-based approaches in learning disabilities

Around 2% of the population have a learning disability, categorised as ‘mental retardation’ in the ICD / DSM classification systems. Mental disorders are at least two to four times more prevalent in people with learning disability compared to the general population. To increase numbers of people with learning disability access generic mental health services, due to philosophies of equity of access and normalisation. Mental health practitioners may address the problem of learning disabilities directly or help people deal with indirect outcomes, such as poor self-concept or even self-harm. Learning disabilities affect both adults and children and can impact on a person’s self-esteem as well as their education and competency. People with learning disabilities may also have co-morbidities. Learning disability is manifested by two components: low cognitive ability and diminished social competence. Both factors are profoundly affected by social and cultural influences. Unlike other ICD 10 mental health disorders, it is difficult to specify detailed clinical diagnostic criteria for learning disability. After considering the cultural norms of a particular individual, mental health practitioners often estimate the intelligence quotient or mental age of the individual using specified levels of cognitive abilities (table).

During the past 20 years, learning disability services have shifted from the hospital to specialist community services. Three key changes occurred with this shift: (1) the introduction of “car management,” (2) the creation of packages of social, educational and developmental care, and (3) allocating “physical care” to primary healthcare and “mental health care” to specialist health services. In the era of evidence-based medicine and clinical governance, each of these changes should be based on research evidence. Evidence-based strategies might lead to constructive change for people with learning disabilities, but evidence about effective interventions is limited and it may be difficult to extrapolate findings from research in the general population or in people with other mental difficulties. This lack of an evidence-base is of relevance to psychiatrists and psychologists practising in an era when “political correctness” and users’ views may compete with evidence gained from more rigorous sources. This editorial examines why it is difficult to obtain rigorous research evidence on learning disability interventions.

Research context

As in many other fields of mental health, evidence in the field of learning disabilities is constrained by ethical concerns over capacity and consent. Large randomised trials are not always practical or acceptable given the nature of patients and interventions, yet there is a desire to incorporate more evidence into practice.

There are several difficulties establishing an evidence-base in learning disabilities. These include transfer of knowledge from other disciplines, mental health co-morbidities, and service delivery practicalities. Other fields of mental health may encounter similar problems. The main difference in learning disabilities is that many disciplines work side by side, some with a historical grounding in empirical research and others with a more theoretical or anecdotal evidence-base. Almost all evidence-based practice for learning disability has been transferred directly from adult psychiatry or mental health services, but this may not always be beneficial for people with learning disabilities. This population may have special needs. For example, a comparison of intensive and standard case management in severe mental illness found no outcome differences for people with learning disabilities. This population may have special needs.

Levels of cognitive abilities

<table>
<thead>
<tr>
<th>Category</th>
<th>Mental retardation level</th>
<th>IQ range</th>
<th>Mental age (years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>F70</td>
<td>Mild</td>
<td>50 to 69</td>
<td>9 to under 12</td>
</tr>
<tr>
<td>F71</td>
<td>Moderate</td>
<td>35 to 49</td>
<td>6 to under 9</td>
</tr>
<tr>
<td>F72</td>
<td>Severe</td>
<td>20 to 34</td>
<td>3 to under 6</td>
</tr>
<tr>
<td>F73</td>
<td>Profound</td>
<td>Less than 20</td>
<td>Less than 3</td>
</tr>
</tbody>
</table>

The full text of Clinical Evidence is updated monthly online at www.clinicalevidence.com. Information on subscriptions is available from CEsubscribers@bmjgroup.com, ph +44(0)20 7383 6270 (or, for North and South America, clinevid@pmds.com, ph 1-800-373-2897). Orders can also be made online.
were significantly better after intensive case management. A similar trial compared assertive and standard community approaches in learning disability services, but the evaluators encountered several difficulties. They concluded that before learning disability services can be adequately evaluated, fundamental changes in attitudes towards research are needed in this field.

Good evidence is definitely needed. Although most mental health workers agree that people with learning disabilities require specialist services, the nature and delivery of these services is far from clear. There have been many changes in recent years, including the expansion of community teams, reduction of hospital beds and development of specialist in-patient assessment services with controlled access to beds. These changes are by no means uniform – and we have little idea of their impact. We need common goals and outcomes to evaluate smaller locally accessible community services, but this is difficult in the complex and multidisciplinary field of learning disabilities. It is also difficult to determine the prevalence of mental disorders in people with learning disability. There is continuing debate as to whether behaviour disorder constitutes an environmental problem or a developmental disorder, for instance.

All of these contextual factors make it difficult to find good evidence in the field of learning disabilities. There are also some practical problems with the quality of evidence in this field. The main practical difficulties involve ethical considerations, methodological problems, and service capacity.

Ethical dilemmas
Randomisation is now better accepted in many mental health disciplines, but it is a major ethical issue in the field of learning disability. Many purchasers and service providers feel that it would be wrong to deprive a person of a “necessary” service. There may also be concerns that well established relationships between service users and carers would be wrongly compromised by randomising patients.

Campbell et al suggest that complex interventions can be evaluated using a systematic controlled trial methodology. But some learning disabilities providers believe that services do not need to be evaluated or the most effective interventions trialled, because their value is self-evident. In our experience with the TACTILD trial, providers who did not take part “on ethical grounds” often said that denial of treatment was unethical, as ipso facto, it must be effective.

Informed consent may also be a problem, with participants being less competent to provide consent than the general population. This problem permeates many other mental health fields, such as work with youths and older people. However, among older people and youth, problems with informed consent may be limited to particular life stages. A person with learning disability will have difficulty providing informed consent throughout their lifetime. Similarly, relatives are often involved in learning disabilities services, either as the primary carer or as a significant contact. This means that, as in studies of young people, a second layer of informed consent is often needed.

Methodology
A wide range of disciplines are involved in the field of learning disability, some of which do not have a strong research tradition. There is a greater reliance on “expert opinion” than in some other mental health fields. There is also significant variation in resources and practice between teams. Even the definitions of different treatments may differ between practice teams. Services rarely define their practices operationally.

Another practical difficulty is the relatively long time period needed to detect changes in learning disabilities. Due to the low prevalence of certain conditions, sample sizes may also be considered small by traditional standards. The variety of disciplines involved in learning disability services and the variation and complexity of the services offered comprises a unique difficulty when implementing evidence-based medicine.

Service capacity
Currently, new learning disability services emerge only where there are strong supportive voices. This “expert opinion” is not necessarily based on high quality evidence. This is of increasing importance in the clinical governance era, where services with no scientific basis for their continuation may be withdrawn. Learning disabilities workers often acknowledge the need for high quality research, but resources are limited. It may not be justified to simply transfer the results of evidence-based practice from standard psychiatric services to learning disability services. It is likely to be more appropriate to develop evidence-based practices specifically for the learning disabled population, especially for those with a moderate or severe level of learning disability.

Evidence needs
Learning disability spans the boundaries between health and social care; specialist health and more general health services, and between child and adult services. As in other fields of mental health, an evidence-based philosophy is needed to develop and maintain high quality services. Questions of cost-effectiveness and cost-benefit also need to be addressed. Adequate research funding is fundamental to this process, necessitating a change in service culture. The need and intention to evaluate must become the norm, not the exception. Without open questioning of current practice, learning disability services will be governed by opinion and product champions instead of a formal evidence-base.

Many mental health professionals have embraced evidence-based philosophies, but the field of learning disabilities has a little “catching up” to do. Promoting and developing rigorous academic research takes time. Despite the problems outlined here, the task is by no means impossible, provided there is ongoing multidisciplinary professional enthusiasm, cooperation and collaboration between users, carers, academic institutions, and health agencies.


Correspondence to: Patricia Oliver, Department of Psychological Medicine, Faculty of Medicine, Imperial College, London, UK. poliver@ic.ac.uk.


ACKNOWLEDGEMENTS
Some of the ideas in this piece are based on the article: Oliver PC, Piachaud J, Done J et al. Difficulties in conducting a randomized controlled trial of health service interventions in intellectual disability: implications for evidence-based practice. Journal of Intellectual Disability Research 2002; 46: 340–5. We thank the North Thames Region R & D for original funding and Helen Bond, Senior Library Assistant, Hertfordshire Partnership NHS Trust, for her assistance throughout the TACTILD project.
Difficulties developing evidence-based approaches in learning disabilities

Patricia C Oliver, Jack Piachaud, D John Done, Adrienne Regan, Sherva E Cooray and Peter J Tyrer

Evid Based Mental Health 2003 6: 37-39
doi: 10.1136/ebmh.6.2.37

Updated information and services can be found at:
http://ebmh.bmj.com/content/6/2/37

These include:

References
This article cites 6 articles, 4 of which you can access for free at:
http://ebmh.bmj.com/content/6/2/37#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections
EBMH Notebook (73)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/